York, U.K. 5 July 2021: Abingdon Health plc (AIM: ABDX) (“Abingdon” or “the Company”), a leading international developer
York, U.K. 5 July 2021: Abingdon Health plc (AIM: ABDX) (“Abingdon” or “the Company”), a leading international developer
York, U.K. 9th July 2021: Abingdon Health plc (“the Company”), a leading international developer
AbC-19TM able to detect different levels of antibody response to the AstraZeneca and Pfizer vaccines as well as those post-infection
York, U.K. 9 August 2021: Abingdon Health plc (AIM: ABDX), a leading international developer
Contract manufacturing for CE marked self-test to monitor antibody status Abingdon Health plc (AIM: ABDX)
Today Abingdon Health's CEO, Chris Yates, spoke with ShareBuyers, an investor